Abstract

This 12-week, unmasked, non-randomized study of three serial 1.9 mg subconjunctival doses of Palomid 529 in neovascular AMD participants who have not responded to conventional anti-VEGF treatments has completed the study objectives. The protocol has been terminated and the results have been published. The study drug was well tolerated and formed a depot at the site of injection. There were no ocular or sytemic toxicity concerns. Although this study was not designed to determine efficacy, there appeared to be no clinical benefit in terms of visual acuity or reduction in macular fluid in our small, short-term study of five participants.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIAEY000523-02
Application #
8737682
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2013
Total Cost
$54,370
Indirect Cost

  Institution

Name
U.S. National Eye Institute
Department
Type
DUNS #
City
State
Country
Zip Code

  Publications

Dalal, Monica; Jacobs-El, Naima; Nicholson, Benjamin et al. (2013) Subconjunctival Palomid 529 in the treatment of neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 251:2705-9
Nicholson, Benjamin; Noble, Jason; Forooghian, Farzin et al. (2013) Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 58:103-26
Ardeljan, Daniel; Meyerle, Catherine B; Agron, Elvira et al. (2013) Influence of TIMP3/SYN3 polymorphisms on the phenotypic presentation of age-related macular degeneration. Eur J Hum Genet :
Wang, Vinson M; Rosen, Richard B; Meyerle, Catherine B et al. (2012) Suggestive association between PLA2G12A single nucleotide polymorphism rs2285714 and response to anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration. Mol Vis 18:2578-85
Cukras, Catherine A; Petrou, Philip; Chew, Emily Y et al. (2012) Oral minocycline for the treatment of diabetic macular edema (DME): results of a phase I/II clinical study. Invest Ophthalmol Vis Sci 53:3865-74
Toy, Brian C; Koo, Euna; Cukras, Catherine et al. (2012) Treatment of nonneovascular idiopathic macular telangiectasia type 2 with intravitreal ranibizumab: results of a phase II clinical trial. Retina 32:996-1006
Wei, Lai; Liu, Baoying; Tuo, Jingsheng et al. (2012) Hypomethylation of the IL17RC promoter associates with age-related macular degeneration. Cell Rep 2:1151-8
Krishnadev, Nupura; Forooghian, Farzin; Cukras, Catherine et al. (2011) Subconjunctival sirolimus in the treatment of diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 249:1627-33
Liu, Baoying; Wei, Lai; Meyerle, Catherine et al. (2011) Complement component C5a promotes expression of IL-22 and IL-17 from human T cells and its implication in age-related macular degeneration. J Transl Med 9:1-12
Liu, Melissa M; Agrón, Elvira; Chew, Emily et al. (2011) Copy number variations in candidate genes in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 52:3129-35

Showing the most recent 10 out of 11 publications